Breaking News Instant updates and real-time market news.

IBM

IBM

$146.54

-0.29 (-0.20%)

, IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

17:32
10/17/17
10/17
17:32
10/17/17
17:32

On The Fly: After Hours Movers

UP AFTER EARNINGS: IBM (IBM), up 4.8%... Interactive Brokers (IBKR), up 1.5%. ALSO HIGHER: STRATA Skin Sciences (SSKN), up 25.8% after it announced an agreement with MedResults Network... Hi-Crush Partners (HCLP), up 11.7% after it resumed its dividend with a 15c payout and announced a $100M share repurchase. DOWN AFTER EARNINGS: Select Comfort (SCSS), down 4.5%... Navient (NAVI), down 3.8%... Cree (CREE), down 2.3%. ALSO LOWER: Akari Therapeutics (AKTX), down 14.1% after it filed to sell common stock... MobileIron (MOBL), down 10.5% after it said that CEO Barry Mainz will leave the company and guided for Q3 revenue below consensus estimates... Fogo De Chao (FOGO), down 3.7% after it guided for Q3 earnings per share below consensus estimates and cut its earnings guidance for fiscal 2017.

IBM

IBM

$146.54

-0.29 (-0.20%)

IBKR

Interactive Brokers

$47.40

-0.32 (-0.67%)

SSKN

Strata Skin Sciences

$1.75

-0.04 (-2.23%)

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

SCSS

Ticker changed to SNBR

$30.38

-0.17 (-0.56%)

NAVI

Navient

$12.20

0.47 (4.01%)

CREE

Cree

$29.34

0.06 (0.20%)

AKTX

Akari Therapeutics

$6.40

-0.08 (-1.23%)

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

FOGO

Fogo De Chao

$12.05

0.1 (0.84%)

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 01

    Nov

  • 15

    Nov

  • 18

    Oct

IBM IBM
$146.54

-0.29 (-0.20%)

09/12/17
MSCO
09/12/17
NO CHANGE
MSCO
Overweight
Morgan Stanley sees new evidence of scaling of IBM's Watson Health
After hosting a meeting with Deborah DiSanzo, General Manager of IBM Watson Health, Morgan Stanley analyst Katy Huberty noted that the unit grew patients that used cognitive technologies by ten times in one year to 40,000 from 4,000. Additionally, the number of hospitals using Watson for Oncology and Watson for Genomics more than doubled, to 89 from 27 last year, added Huberty. The analyst, who sees IBM as uniquely positioned to address the $2T of wasted spending on health care, keeps an Overweight rating on the stock.
09/05/17
UBSW
09/05/17
NO CHANGE
Target $152
UBSW
Neutral
Blockchain and cognitive computing IBM's best recovery chance, says UBS
UBS analyst Steven Milunovich noted IBM's (IBM) legacy business remains in decline but he thinks technologies such as blockchain and cognitive computing are its best hope for recovery. The analyst sees blockchain as a differentiated growth opportunity and he believes IBM is ahead of Microsoft (MSFT), which is also looking to monetize the technology. Milunovich said IBM's earnings momentum is mediocre and he remains concerned about the company's 2018 outlook. Milunovich maintained his Neutral rating and $152 price target on IBM shares.
09/26/17
KEYB
09/26/17
NO CHANGE
KEYB
Accenture, IBM to benefit from shift to AI, says KeyBanc
KeyBanc analyst Arvind Ramnani says that while the promise of Artificial Intelligence is exciting, the path is complex, which he believes provides a "unique opportunity" for IT Services firms that can accelerate its adoption. The analyst thinks Accenture (ACN), IBM (IBM), DXC Technology (DXC), and EPAM Systems (EPAM), among others, could benefit from the shift to AI.
10/16/17
10/16/17
DOWNGRADE
Target $72

Underweight
Morgan Stanley says lower for longer the 'new normal' for agencies, cuts Omnicom
As previously reported, Morgan Stanley analyst Benjamin Swinburne downgraded Omnicom (OMC) to Underweight from Equal Weight and lowered his price target on the shares to $72 from $86. The analyst, who disagrees with the consensus view that organic growth will return for the industry in 2018, thinks "lower for longer" is the "new normal," noting that ad agencies are part of the supply chain to major brands pressured by shifting consumer behavior and that many key advertising verticals are facing secular challenges. Swinburne also sees growing risk from major consulting firms, particularly Accenture (ACN) but also IBM (IBM), who are attempting to capture marketing budget that might have otherwise gone to agencies. He also cut his price target on peer Interpublic Group (IPG) to $22 from $24, though he keeps an Equal Weight rating on that stock to account for its strategic optionality.
IBKR Interactive Brokers
$47.40

-0.32 (-0.67%)

04/19/17
KBWI
04/19/17
DOWNGRADE
Target $38
KBWI
Market Perform
Interactive Brokers downgraded to Market Perform at Keefe Bruyette
Keefe Bruyette analyst Kyle Voigt downgraded Interactive Brokers to Market Perform from Outperform and lowered his price target for the shares to $38 from $41. The analyst cut his estimates following the company's Q1 results.
04/03/17
WELS
04/03/17
DOWNGRADE
WELS
Underperform
Interactive Brokers downgraded to Underperform Perform at Wells Fargo
Wells Fargo analyst Christopher Harris downgraded Interactive Brokers to Underperform from Market Perform saying the company is likely to face near-term challenges with the wind-down of its Market Making operation and commissions growth. The analyst expects the stock "to struggle during this transition period." He lowered his price target range for Interactive shares to $30-$34 from $35-$39.
01/10/17
GSCO
01/10/17
UPGRADE
Target $40
GSCO
Neutral
Interactive Brokers upgraded to Neutral from Sell at Goldman
Goldman analyst Conor Fitzgerald upgraded Interactive Brokers to Neutral and raised its price target to $40 from $39 citing inline valuation with peers.
04/19/17
04/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ultragenyx (RARE) was downgraded to Neutral from Buy at H.C. Wainwright and to Neutral from Outperform at Wedbush. 2. Grainger (GWW) downgraded to Underperform on pricing risks at Credit Suisse with analyst Andrew Buscaglia telling investors he sees more uncertainty around its pricing strategy for its highest margin mid-sized customers and continued gross margin declines in 2018 that will weigh on shares. Buscaglia believes Grainger is the most susceptible to the Amazon (AMZN) threat as evidenced by its pricing actions to its more profitable smaller-medium sized customers and said its move online makes it more susceptible to competitive pricing. 3. Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette with analyst Kyle Voigt citing the company's first quarter results. 4. Regions Financial (RF) downgraded to In Line from Outperform at Evercore ISI with analyst John Pancari citing limit upside to valuation given mounting earnings headwinds. 5. Sirius XM (SIRI) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Benjamin Swinburne telling investors the business is maturing and growth is slowing. Swinburne said Sirius is executing well, but the benefit from new car turnover has likely peaked and not longer adds material to the subscription base, and adds used car growth has also peaked. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SSKN Strata Skin Sciences
$1.75

-0.04 (-2.23%)

02/21/17
RODM
02/21/17
INITIATION
Target $1.5
RODM
Buy
STRATA Skin Sciences assumed with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis assumed coverage of STRATA Skin Sciences with a Buy rating and $1.50 price target.
HCLP Hi-Crush Partners
$8.95

0.25 (2.87%)

07/20/17
FBCO
07/20/17
NO CHANGE
Target $12
FBCO
Outperform
Hi-Crush Partners price target lowered to $12 from $24 at Credit Suisse
Credit Suisse analyst James Wicklund lowered his price target for Hi-Crush Partners to $12 from $24, citing additions to capacity that could come on the market over the next 18 months. The analyst reiterates an Outperform rating on the shares.
09/25/17
09/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) initiated with a Neutral at Citi. 2. CoreSite Realty (COR) initiated with a Neutral at JPMorgan. 3. Hi-Crush Partners (HCLP) initiated with an Overweight at Piper Jaffray. 4. Zillow (Z, ZG) initiated with a Neutral at Macquarie. 5. Big Lots (BIG) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/17
JANY
09/06/17
INITIATION
Target $10
JANY
Neutral
Hi-Crush Partners initiated with a Neutral at Janney Capital
Janney Capital analyst Akil Marsh initiated Hi-Crush Partners with a Neutral and a $10 price target saying downside risks remain and negative sentiment in the frac sand space is not expected to change anytime soon.
09/25/17
PIPR
09/25/17
INITIATION
Target $11.75
PIPR
Overweight
Hi-Crush Partners initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst John Watson started Hi-Crush Partners with an Overweight rating and $11.75 price target. PropStream should continue to gain market share and Hi-Crush stands to benefit from its first mover advantage in West Texas, the analyst contends.
SCSS Ticker changed to SNBR
$30.38

-0.17 (-0.56%)

10/12/17
PIPR
10/12/17
NO CHANGE
PIPR
Mattress names weak after Piper finds slower growth for September
Piper Jaffray's monthly mattress survey for September, which includes a sampling of mattress retailers across the U.S. representing hundreds of stores, showed slower growth for September, analyst Peter Keith told investors in a research note last night. The survey continues a trend that started with Labor Day weekend and marks a deceleration from the "healthy trend" seen in May through August, Keith writes. He believes "weak" mattress units are the issue, with September showing the largest unit decline in his firm's survey year-to-date. The analyst suspects unit weakness is primarily at the low-end, noting that Tempur-Pedic (TPX) sales "remained healthy." Keith kept Overweight ratings on Tempur-Pedic, Select Comfort (SCSS) and Leggett & Platt (LEG). Mattress unit weakness at the low-end would be most unfavorable to Leggett & Platt, the analyst cautions. Shares of Tempur-Pedic and Select Comfort are both down 5% in early trading while Leggett & Platt is down 1%.
10/02/17
RAJA
10/02/17
UPGRADE
Target $35
RAJA
Outperform
Select Comfort upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Budd Bugatch upgraded Select Comfort to Outperform and established a $35 price target. The analyst said the company has delivered on sales momentum through the first half and believes new product introductions are resonating with customers. Further, Bugatch sees an opportunity to improve performance and drive earnings growth through the company's vertically integrated operating model.
09/12/17
PIPR
09/12/17
NO CHANGE
Target $38
PIPR
Overweight
Select Comfort data points 'decent' despite recent selloff, says Piper Jaffray
Piper Jaffray analyst Peter Keith says that while Select Comfort shares are down 14% since August 11, he's not aware of any near-term negative data points except for some recent negative social media posts and the lack of any new Sleep 360 product launched. Data points look "decent," with a Google Search analysis for Q3-to-date showing improvement from Q2 and negative social media posts moderating in recent weeks, Keith tells investors in a research note. He believes Select Comfort's average revenue per unit gains should continue as Sleep 360 beds drive a higher attach rate of adjustable bases. The analyst says he remains comfortable with his above-consensus Q3 comp and sales estimates for Select Comfort. Keith keeps an Overweight rating on the shares with a $38 price target.
07/19/17
BOFA
07/19/17
UPGRADE
Target $35
BOFA
Neutral
Select Comfort upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Curtis Nagle upgraded Select Comfort to Neutral and raised its price target to $35 from $21.50 saying he believes underlying demand is improving, has increased confidence on earnings, and expects a potential comp lift from the new 360 product line. The analyst believes management is making progress on gross margin initiatives and said a recent bedding survey suggests strong brand affinity and potential market share capture following the termination of the Mattress Firm contract.
NAVI Navient
$12.20

0.47 (4.01%)

10/17/17
SBSH
10/17/17
INITIATION
Target $20
SBSH
Buy
Navient initiated with a Buy at Citi
Citi analyst Arren Cyganovich started Navient with a Buy rating and $20 price target. The shares are "substantially undervalued" relative to the intrinsic value of the company's cash flows from its run-off loan portfolios, Cyganovich tells investors in a research note.
10/05/17
COMP
10/05/17
DOWNGRADE
COMP
Neutral
Navient downgraded to Neutral from Buy at Compass Point
09/08/17
FBCO
09/08/17
UPGRADE
Target $16.5
FBCO
Outperform
Navient upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Moshe Orenbuch upgraded Navient to Outperform saying shares are "too cheap" after a 20% selloff year-to-date and maintained a $16.50 price target. The analyst said has several positives including strong cash flows should lead to substantial repurchases, government loan margin supported by improved 3/1 month libor spread, reduced regulatory risk, and a call option on tax reform.
09/05/17
COMP
09/05/17
UPGRADE
Target $16.5
COMP
Buy
Navient upgraded to Buy from Neutral at Compass Point
Compass Point upgraded Navient to Buy from Neutral with a $16.50 price target. Analyst Michael Tarkan believes the regulatory environment for student lenders/servicers will become more benign over the next few years following the Department of Educations announcement that it intends to end two information sharing agreements with the CFPB related to oversight of federal loans. The analyst expects Navient to be a beneficiary of reduced regulation and said the recent pullback in shares provides an favorable entry point.
CREE Cree
$29.34

0.06 (0.20%)

10/12/17
GSCO
10/12/17
NO CHANGE
GSCO
Goldman Sachs Tactical Trades ahead of earnings
Goldman analysts led by John Marshall highlight some of the firm's most out-of-consensus opportunities ahead of the earnings season. The firm sees potential for upward earnings revisions to drive share upside in Caterpillar (CAT), ENGlobal (ENTG), McDonald's, (MCD) and Netflix (NFLX) and downwards earnings revisions to drive downside in Grainger (GWW), Cree (CREE), and Tesla (TSLA).
10/06/17
10/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spirit Airlines (SAVE) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying the company's revenue outlook "may face greater downside risk" than peers given the competitive intensity of its markets. 2. Albemarle (ALB) downgraded to Neutral from Conviction Buy at Goldman Sachs with analyst Robert Koort saying the company over the past two years has transformed from a value-oriented chemical stock into a "thematic growth engine" as investors shifted their focus to the potential of an electric vehicle revolution. 3. Cree (CREE) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster citing valuation. 4. Valero (VLO) downgraded to Neutral from Overweight at JPMorgan with Phil Gresh citing valuation following the recent rally. 5. Walgreens Boots Alliance (WBA) downgraded to Equal Weight at Morgan Stanley with analyst Ricky Goldwasser saying he expects the company's guidance to come in below consensus estimates when it is provided later this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/17
JPMS
10/06/17
DOWNGRADE
Target $28
JPMS
Underweight
Cree downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster downgraded Cree to Underweight citing valuation. The stock's 36% rally since the resignation of CEO Swoboda "seems rational but premature," Coster tells investors in a research note. He recommends Cree as a "tactical short" saying the "reality of near-term earnings could deflate the multiple" post this quarter's report. The analyst raised his price target for the shares to $28 from $23.
08/23/17
ROTH
08/23/17
NO CHANGE
Target $28
ROTH
Buy
Roth Capital remains a buyer of Cree on a potential Wolfspeed spinoff
Roth Capital analyst Craig Irwin notes that Cree reported essentially inline Q4 results, with Q1 guidance that primarily reflects increasing spend to support growth for Wolfspeed. The analyst reiterates a Buy rating on the shares for the significant value creation potential in a Wolfspeed spinoff, which would also allow increased focus on the core LED chips and components and lighting products businesses. Irwin also lowered his price target on the shares to $28 from $29.
AKTX Akari Therapeutics
$6.40

-0.08 (-1.23%)

06/27/17
ADAM
06/27/17
NO CHANGE
Target $15
ADAM
Buy
Akari Therapeutics price target lowered to $15 from $33 at Canaccord
Canaccord analyst Arinda Lee lowered her price target on Akari Therapeutics to $15 from $33 following its Coversin data presentation at the EHA meeting. Lee said Coversin's efficacy is competitive, as the data indicated meaningful benefit in PNH without generating neutralizing antibodies or serious adverse events, but its pushed out timelines for launch and the lowered probability of success due to aggressive competition caused her to lower her targets. Lee reiterated her Buy rating on Akari Therapeutics shares.
05/31/17
05/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Donaldson (DCI) upgraded to Buy from Hold at Jefferies with analyst Laurence Alexander saying he sees "increasing evidence" the company's end-markets are exiting the multi-year trough and believes operating leverage should translate into above-average compound growth over the next few years. He recommends building positions in the stock during the second half of 2017. 2. VMware (VMW) upgraded to Outperform from Neutral at Baird with analyst Jason Noland citing the company's strategic shift to partner with firms rather than compete with the public cloud. 3. Akari Therapeutics (AKTX) upgraded to Neutral from Sell at Chardan. 4. Vale (VALE) upgraded to Buy from Hold at HSBC with analyst Jonathan Brandt saying the recent decline in iron ore prices has mitigated risk, and the focus should now shift to the company's "strong" free cash flow generation and 6% dividend yield. 5. Potbelly (PBPB) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson citing news that Chief Executive Officer Aylwin Lewis is resigning, as he believes new management could reinvigorate performance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/17
CHDN
05/31/17
UPGRADE
CHDN
Neutral
Akari Therapeutics upgraded to Neutral from Sell at Chardan
09/22/17
WBLR
09/22/17
UPGRADE
WBLR
Outperform
Akari Therapeutics upgraded to Outperform from Market Perform at William Blair
William Blair analyst Tim Lugo upgraded Akari Therapeutics to Outperform saying coversin is progressing towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria with an achievable endpoint.
MOBL MobileIron
$3.80

-0.1 (-2.56%)

04/25/17
BNCH
04/25/17
INITIATION
Target $7
BNCH
Buy
MobileIron initiated with a Buy at Benchmark
Benchmark analyst Scott Searle initiated MobileIron with a Buy rating and $7 price target, saying he views it as a leader in Enterprise Mobility Management trading at a reasonable valuation.
FOGO Fogo De Chao
$12.05

0.1 (0.84%)

12/19/16
JPMS
12/19/16
NO CHANGE
JPMS
JPMorgan says sell Casual Dining names after recent rally
JPMorgan analyst John Ivankoe believes fundamentals in the Casual Dining space have not improved as much as the current stock prices suggest. He recommends fading the rally across the sector, even the names he rates Overweight. Ivankoe has Neutral ratings on Darden (DRI), Cheesecake Factory (CAKE), Texas Roadhouse (TXRH) and Fogo De Chao (FOGO) and Overweight ratings on Brinker (EAT) and Bloomin' Brands (BLMN). Supply growth in the Casual Dining space is increasing across the industry faster than demand while commodity cost benefits are moderating, Ivankoe tells investors in a research note.
05/04/17
05/04/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Solar (FSLR) upgraded to Buy from Neutral at BofA/Merrill with analyst Krish Sankar saying First Solar's execution has improved and said the low cost Series 6 product could lead to better margins starting in the second quarter of 2018. Sankar also told investors First Solar's valuation is attractive and the balance sheet has strengthened. 2. Fogo De Chao (FOGO) upgraded to Buy from Hold at Canaccord with analyst Lynne Collier saying she sees an improved outlook for the overall industry in the next 12-24 months and she has increased confidence in the company's ability to drive market share gains. Collier raised her price target to $20 from $16 on Fogo de Chao shares. 3. Carlyle Group (CG) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Robert Lee citing the "strong" first quarter results and accrued carry. 4. Regions Financial (RF) upgraded to Buy from Neutral at BofA/Merrill with analyst Erika Najarian saying the market is undervaluing a "significant capital return story" following the year-to-date underperformance relative to peers. The analyst sees upside to the dividend and thinks Regions can return 20% of its market capitalization over the next two years. Her price target of $17 implies 20% upside from current levels. 5. Bunge (BG) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan citing a balanced risk/reward following the 11% post-earnings selloff. The analyst keeps a $70 price target for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/17
ADAM
05/04/17
UPGRADE
ADAM
Buy
Fogo De Chao upgraded to Buy from Hold at Canaccord
05/04/17
ADAM
05/04/17
UPGRADE
Target $20
ADAM
Buy
Fogo De Chao upgraded to Buy at Canaccord
As reported previously, Canaccord analyst Lynne Collier upgraded Fogo de Chao to Buy from Hold ahead of Q1 results. She sees an improved outlook for the overall industry in the next 12-24 months and she has increased confidence in the company's ability to drive market share gains. Collier raised her price target to $20 from $16 on Fogo de Chao shares.

TODAY'S FREE FLY STORIES

KW

Kennedy Wilson

$19.40

0.3 (1.57%)

06:02
11/22/17
11/22
06:02
11/22/17
06:02
Hot Stocks
Kennedy Wilson acquires apartment community in Greater Bellevue for $135M »

Kennedy Wilson has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$18.85

0.23 (1.24%)

05:55
11/22/17
11/22
05:55
11/22/17
05:55
Hot Stocks
KBR JV awarded FEED contract for Absheron Field in Azerbaijan »

KBR announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

05:52
11/22/17
11/22
05:52
11/22/17
05:52
Downgrade
Salesforce rating change  »

Salesforce downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GG

Goldcorp

$13.23

-0.05 (-0.38%)

05:49
11/22/17
11/22
05:49
11/22/17
05:49
Downgrade
Goldcorp rating change  »

Goldcorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

05:46
11/22/17
11/22
05:46
11/22/17
05:46
Upgrade
Terreno Realty rating change  »

Terreno Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

PAAS

Pan American Silver

$15.20

0.22 (1.47%)

05:42
11/22/17
11/22
05:42
11/22/17
05:42
Upgrade
Pan American Silver rating change  »

Pan American Silver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 05

    Dec

CBRL

Cracker Barrel

$150.79

-6.41 (-4.08%)

05:41
11/22/17
11/22
05:41
11/22/17
05:41
Downgrade
Cracker Barrel rating change  »

Cracker Barrel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$8.22

-1.03 (-11.14%)

05:39
11/22/17
11/22
05:39
11/22/17
05:39
Recommendations
Vipshop analyst commentary  »

Vipshop price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$43.80

-0.5 (-1.13%)

05:35
11/22/17
11/22
05:35
11/22/17
05:35
Upgrade
New Jersey Resources rating change  »

New Jersey Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBPB

Potbelly

$12.15

-0.15 (-1.22%)

05:31
11/22/17
11/22
05:31
11/22/17
05:31
Recommendations
Potbelly analyst commentary  »

Potbelly shares remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

05:29
11/22/17
11/22
05:29
11/22/17
05:29
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

YNDX

Yandex

$34.28

0.57 (1.69%)

05:28
11/22/17
11/22
05:28
11/22/17
05:28
Hot Stocks
Yandex appoints Greg Abovsky as COO »

Yandex announced changes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$21.39

-0.42 (-1.93%)

05:26
11/22/17
11/22
05:26
11/22/17
05:26
Downgrade
Mallinckrodt rating change  »

Mallinckrodt downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

05:25
11/22/17
11/22
05:25
11/22/17
05:25
General news
FX Action: The dollar has perked up »

FX Action: The dollar…

SIG

Signet Jewelers

$52.79

-23.05 (-30.39%)

05:22
11/22/17
11/22
05:22
11/22/17
05:22
Recommendations
Signet Jewelers analyst commentary  »

Signet Jewelers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

05:19
11/22/17
11/22
05:19
11/22/17
05:19
Recommendations
Axalta Coating analyst commentary  »

Nippon could bid as much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

05:16
11/22/17
11/22
05:16
11/22/17
05:16
Hot Stocks
Axalta Coating confirms takeover talks with Nippon Paint »

Axalta Coating Systems…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLOG

Rand Logistics

$0.59

0.016 (2.80%)

05:15
11/22/17
11/22
05:15
11/22/17
05:15
Hot Stocks
Rand Logistics to be acquired by American Industrial Partners »

Rand Logistics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$52.20

-0.3 (-0.57%)

05:12
11/22/17
11/22
05:12
11/22/17
05:12
Hot Stocks
Scientific Games acquires 11.6M ordinary shares of NYX Gaming »

Scientific Games…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$90.19

-2.88 (-3.09%)

05:12
11/22/17
11/22
05:12
11/22/17
05:12
Recommendations
Analog Devices analyst commentary  »

Analog Devices price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

TEDU

Tarena

$13.36

-2.53 (-15.92%)

05:10
11/22/17
11/22
05:10
11/22/17
05:10
Downgrade
Tarena rating change  »

Tarena downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

05:07
11/22/17
11/22
05:07
11/22/17
05:07
Recommendations
HP Inc. analyst commentary  »

HP Inc. target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

05:05
11/22/17
11/22
05:05
11/22/17
05:05
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

05:03
11/22/17
11/22
05:03
11/22/17
05:03
Recommendations
Axalta Coating, AkzoNobel, Berkshire Hathaway, Berkshire Hathaway analyst commentary  »

Axalta remains potential…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

BRK.A

Berkshire Hathaway

$275,000.00

2995 (1.10%)

BRK.B

Berkshire Hathaway

$183.18

1.55 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

04:57
11/22/17
11/22
04:57
11/22/17
04:57
Recommendations
Salesforce analyst commentary  »

Salesforce positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.